Apollomics Inc. (NASDAQ:APLM) Sees Significant Increase in Short Interest

Apollomics Inc. (NASDAQ:APLM) was the recipient of a large increase in short interest in June. As of June 30th, there was short interest totaling 5,144 shares, an increase of 104.5% from the June 15th total of 2,515 shares. Approximately 0.2% of the shares of the company are short sold. Based on an average daily volume of 21,851 shares, the days-to-cover ratio is currently 0.2 days.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Apollomics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

Apollomics Stock Performance

Apollomics stock opened at $16.91 on Wednesday. The company has a 50-day moving average price of $16.20 and a 200 day moving average price of $17.55. Apollomics has a 12-month low of $3.66 and a 12-month high of $42.12.

Hedge Funds Weigh In On Apollomics

An institutional investor recently bought a new position in Apollomics stock. Kestra Advisory Services LLC bought a new stake in Apollomics Inc. (NASDAQ:APLM) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 4,380 shares of the company’s stock, valued at approximately $82,000. Kestra Advisory Services LLC owned approximately 0.40% of Apollomics as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 19.13% of the company’s stock.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.